Overview

A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Patients With Prader-Willi Syndrome

Status:
Terminated

Trial end date:
2019-06-10

Target enrollment:

Participant gender:

Summary

The objective of this study is to assess the long-term safety and tolerability of Cannabidiol Oral Solution (CBD) in patients with Prader-Willi Syndrome.

Phase:

Phase 2

Details

Lead Sponsor:

Benuvia Therapeutics Inc.
INSYS Therapeutics Inc

Treatments:

Cannabidiol
Pharmaceutical Solutions